4502 — Takeda Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual cashflow statement for Takeda Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	—	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	376,171	230,166	317,038	144,197	108,143
Depreciation
Non-Cash Items	12,308	252,109	327,626	182,842	452,700
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	62,781	57,679	-331,908	-338,697	-265,057
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	1,010,931	1,123,105	977,156	716,344	1,057,182
Capital Expenditures	-236,468	-186,037	-633,689	-480,730	-347,841
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	629,998	-12,088	26,587	16,868	-19,219
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	393,530	-198,125	-607,102	-463,862	-367,060
Financing Cash Flow Items	-142,352	-108,592	-117,732	-126,478	-129,633
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1,088,354	-1,070,265	-709,148	-354,416	-751,425
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	328,608	-116,527	-316,165	-75,730	-72,688